concept

FCGRT

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about FCGRT: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

217Connections

1Hypotheses

1Analyses

50Outgoing

50Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	FCGRT
Key Genes/Proteins	FcRn, Fcrn, Immunoglobulin G, IgG, IGG, FCRN
Related Diseases	Monoclonal Antibody Persistence, Igg Half-Life, Fc-Based Biologics Bioavailability, plasma half-life

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    FCGRT["FCGRT"]
    style FCGRT fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    FCGRT -->|"encodes"| IGG([IGG])
    FCGRT -->|"encodes"| FCRN([FCRN])
    FCGRT -->|"modulates"| Anti_SARS_CoV_2_Antibodies["Anti-SARS-CoV-2 Antibodies"]
    FCGRT -->|"expressed in"| FcRn["FcRn"]
    FCGRT -->|"expressed in"| BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"]
    FCGRT -->|"regulates"| ANTIBODY_HALF_LIFE["ANTIBODY HALF-LIFE"]
    FCGRT -->|"mediates"| Antibody_Mediated_Immunity["Antibody-Mediated Immunity"]
    FCGRT -->|"target for"| THERAPEUTIC_TARGET["THERAPEUTIC_TARGET"]
    FCGRT -->|"involved_in"| SARS_COV_2_IMMUNITY["SARS-COV-2 IMMUNITY"]
    FCGRT -->|"regulates"| IVIg_Effectiveness(IVIg Effectiveness)
    h_23a3cc07["h-23a3cc07"] -->|"targets"| FCGRT
    CIDP["CIDP"] -->|"regulates"| FCGRT

Outgoing (146)

Target	Relation	Type	Str
FcRn	associated_with	protein	1.00
Fcrn	encodes	protein	0.95
Immunoglobulin G	binds	protein	0.95
Immunoglobulin G Catabolism	protects_against	process	0.95
Monoclonal Antibody Persistence	mediates	phenotype	0.95
IgG	modulates	protein	0.95
Igg Half-Life	regulates	phenotype	0.95
IGG	encodes	protein	0.95
FCRN	encodes	protein	0.95
Tfrmab-Tnfr	regulates	drug	0.92
Fc-Based Biologics Bioavailability	regulates	phenotype	0.90
TfRMAb fusion protein	regulates	drug	0.90
plasma half-life	regulates	phenotype	0.90
IgG	protects	protein	0.90
Igg-Based Biologics	extends_persistence	protein	0.90
Antibody Half-Life	regulates	phenotype	0.88
Tfrmab	binds	drug	0.88
Fcrn Binding Affinity	involved_in	mechanism	0.87
Anti-SARS-CoV-2 Antibodies	modulates	biomarker	0.85
FcRn	expressed_in	receptor	0.85
ANTIBODY HALF-LIFE	regulates	entity	0.85
Antibody-Mediated Immunity	mediates	process	0.85
Antibody Half-Life Extension	mediates	mechanism	0.85
Ivig Effectiveness	associated_with	phenotype	0.85
anti-SARS-CoV-2 monoclonal antibodies	regulates	protein	0.85
TfRMAb-TNFR	binds	drug	0.85
MYASTHENIA GRAVIS	associated_with	entity	0.85
BLOOD-BRAIN BARRIER	expressed_in	entity	0.85
SARS-CoV-2	associated_with	entity	0.80
GUILLAIN-BARRÉ SYNDROME	associated_with	entity	0.80
CIDP	associated_with	entity	0.80
MULTIFOCAL MOTOR NEUROPATHY	associated_with	entity	0.80
SARS-COV-2 IMMUNITY	involved_in	entity	0.80
IVIg Effectiveness	regulates	phenotype	0.80
tissue biodistribution	regulates	phenotype	0.80
THERAPEUTIC_TARGET	therapeutic_target	entity	0.80
FcRn_receptor	encodes	protein	0.80
TfRMAb-EPO	binds	drug	0.75
IVIg efficacy	regulates	phenotype	0.75
SARS-CoV-2	interacts_with	entity	0.70
Myasthenia Gravis	associated_with	disease	0.65
Neuropathy	regulates	disease	0.65
Autoimmune	regulates	disease	0.65
Ms	inhibits	disease	0.65
Als	regulates	disease	0.65
Ms	protects_against	disease	0.65
Als	protects_against	disease	0.65
ALS	regulates	disease	0.65
ALS	protects_against	disease	0.65
Als	biomarker_for	disease	0.65

Incoming (71)

Source	Relation	Type	Str
Fc Domain	interacts_with	protein	0.95
Humanized Monoclonal Antibodies	targets	drug	0.90
Tfrmab-Tnfr	interacts_with	drug	0.90
h-23a3cc07	targets_gene	hypothesis	0.90
TfRMAb fusion protein	targets	drug	0.85
h-23a3cc07	targets	hypothesis	0.80
CIDP	regulates	entity	0.60
GOT2	biomarker_for	gene	0.60
CASP3	therapeutic_target	gene	0.60
STAT3	therapeutic_target	gene	0.60
PLK4	associated_with	gene	0.60
AKT	associated_with	gene	0.60
C1QA	activates	gene	0.60
CTSB	activates	gene	0.60
C1QA	expressed_in	gene	0.60
CTSB	expressed_in	gene	0.60
APOC1	activates	gene	0.60
C1QC	activates	gene	0.60
CD14	activates	gene	0.60
CD163	activates	gene	0.60
CTSL	activates	gene	0.60
AND	inhibits	gene	0.60
ACE2	protects_against	gene	0.60
TMPRSS2	protects_against	gene	0.60
AND	protects_against	gene	0.60
AND	associated_with	gene	0.60
IFN	expressed_in	gene	0.60
ASTROCYTES	expressed_in	gene	0.60
ERK	expressed_in	gene	0.60
PARKINSON	therapeutic_target	gene	0.60
ALZHEIMER	therapeutic_target	gene	0.60
GENES	biomarker_for	gene	0.60
AND	regulates	gene	0.60
AND	expressed_in	gene	0.60
GENES	associated_with	gene	0.60
INFLAMMATION	regulates	gene	0.60
NEUROINFLAMMATION	regulates	gene	0.60
ACE2	interacts_with	gene	0.60
ACE2	activates	gene	0.60
cidp	regulates	disease	0.50
PLK4	interacts_with	protein	0.50
Autoimmune	regulates	disease	0.50
Neuropathy	regulates	disease	0.50
SARS	interacts_with	gene	0.50
SARS	regulates	gene	0.50
Infection	regulates	disease	0.50
SARS	activates	gene	0.50
Infection	activates	disease	0.50
Cortex	associated_with	brain_region	0.50
Hippocampus	associated_with	entity	0.50

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu	0.566	neurodegeneration	Blood-brain barrier transport mechanisms

Mentioning Analyses (1)

Scientific analyses that reference this entity

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.566

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease. [PMID:40425446]	Sehlin D, Hultqvist G, Michno W, Aguilar	J Prev Alzheimers Dis	2025	1
A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy [PMID:40020261]	Ana-Sosa-Batiz F, Verma SK, Shafee N, Mi	EBioMedicine	2025	1
The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene [PMID:33717213]	Dalakas MC, Spaeth PJ	Ther Adv Neurol Disord	2021	1
Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human [PMID:33025844]	Low BE, Christianson GJ, Lowell E, Qin W	MAbs	2020	1
Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein P [PMID:41755010]	["Oyegbesan A", "Jagadeesan N", "Chandra	Pharmaceutics	2026	0
ROS-responsive nanogels for brain targeted delivery of icariin in the treatment [PMID:41197818]	["Li X", "Huang J", "Zhou Y", "Chen X",	International journal of pharm	2026	0
A humanized transferrin receptor 1-transferrin model supports functional iron ho [PMID:41338456]	Yesiltepe M, Metkar S, Yin T, Chakrabort	The Journal of biological chem	2026	0
Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next- [PMID:41199078]	["Ranjitha V", "Kumar A", "Kaalappa P"]	Pharmaceutical research	2025	0
A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and acti [PMID:39676023]	["Sehlin D", "Roshanbin S", "Zachrisson	Neurotherapeutics : the journa	2025	0
Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic a [PMID:40715281]	Lee S, Kyung M, Park M, Park S, Lee J, K	Scientific reports	2025	0
Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide [PMID:40403225]	["Fletcher N", "Houston Z", "Chandler P"	Molecular pharmaceutics	2025	0
Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain B [PMID:41031862]	["Guo K", "Cao D", "Marchese-Thomas L",	Bioconjugate chemistry	2025	0
Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope [PMID:41110474]	["David M", "Cohen R", "Beuzelin D", "Fe	Journal of controlled release	2025	0
Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therap [PMID:40807149]	["Ciarmatori N", "Quaranta Leoni F", "Qu	Journal of clinical medicine	2025	0
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746]	["Sanadgol N", "Abedi M", "Hashemzaei M"	Journal of nanobiotechnology	2025	0
A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediate [PMID:39715817]	["Petersen I", "Morrison J", "Petrovic A	Scientific reports	2024	0
RNA therapies for CNS diseases. [PMID:38494152]	["Di Francesco V", "Chua A", "Huang D",	Advanced drug delivery reviews	2024	0
An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission. [PMID:37932271]	["Li W", "Wang T", "Rajendrakumar A", "A	Nature communications	2023	0
Strategies to identify, engineer, and validate antibodies targeting blood-brain [PMID:38007619]	["Choi E", "Shusta E"]	Expert opinion on drug deliver	2023	0
Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Compre [PMID:36077002]	["Ramdani Y", "Lamamy J", "Watier H", "G	International journal of molec	2022	0

FCGRT

Understanding Entity Pages

Wiki Pages (21)

FCGRT — Fc fragment of IgG receptor and transporter

Blood-Brain Barrier Dysfunction in Neurodegeneration

Blood-Brain Barrier Biology and Crossing Strategies

Blood-Brain Barrier Breakdown in Neurodegeneration

blood-brain-barrier-endothelial-cells

Blood-Based Biomarkers for Neurodegeneration

Blood Microbial Signatures in Parkinson's Disease

Blood-Brain Barrier

Blood-Brain Barrier Penetration Technologies Investment Landscape

Anti-Tau Therapeutics

Blood-Brain Barrier in 4R-Tauopathies

ER Stress & UPR Therapeutics Investment Landscape

Blood-Brain Barrier Breakdown as Primary Disease Driver

Protein Aggregation Inhibitors for Neurodegeneration — Investment Landscape Analysis

Blood-Brain Barrier Dysfunction Pathway

Blood p-Tau217 as a Clock for Alzheimer's Disease Onset Timing